1530 On Other Exchanges
Hong Kong

3sbio inc (1530) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company provides TPIAO, a recombinant human thrombopoietin for chemotherapy-induced thrombopenia and immune thrombocytopenia; Ruisiyi, a non-steroidal aromatase inhibitor for breast cancer; EPIAO and SEPO recombinant human erythropoietins to treat anemia; Wanwei, a 5-HT3 receptor antagonist antiemetic drug for vomiting; and Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections. It also offers Inleusin, a recombinant human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up; Etanercept, a recombinant human type II tumor necrosis factor receptor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; BYETTA for the glycemic control in patients with type 2 diabetes; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, the company provides Mandi for the treatment of male-pattern alopecia and alopecia areata; Aiyishu to treat iron-deficiency anemia; Qiming Keli for retinopathy caused by type-2 diabetes; Disu, a bidirectional immunomodulator for the prevention and treatment of chronic bronchitis, cold, and asthma; Jiannipai, a recombinant humanized anti-CD25 monoclonal antibody injection to prevent acute rejection after renal transplantation; and Humulin, a recombinant insulin for diabetes. Further, the company engages in the contract development and manufacturing, trading, project management and consultation, and provision of technology services activities. It has collaboration agreements with Toray Industries, Inc.; Refuge Biotechnologies, Inc.; Samsung Bioepis Co., Ltd.; Verseau Therapeutics, Inc.; and Taiwan Liposome Company, Ltd. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People’s Republic of China.

5,047 Employees
Last Reported Date: 04/30/19
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co-Founder, Chairman, CEO & President
Total Annual Compensation: CNY16.2M
CFO, Executive VP & Executive Director
Total Annual Compensation: CNY12.4M
Senior VP & Executive Director
Total Annual Compensation: CNY2.5M
Compensation as of Fiscal Year 2018.
3sbio inc
3SBio Inc. Proposes Final Dividend for the Year Ended 31 March 2019

3SBio Inc. proposed to declare a final dividend of 0.5 Hong Kong cent per share for the year ended 31 March 2019, at its annual general meeting to be held on August 6, 2019.

3SBio Inc. Announces Management Changes

3SBio Inc. at its annual general meeting held on June 20, 2019 appointed Mr. WANG Rui as an independent non-executive director of the company. Mr. MA Jun has tendered his resignation as an independent non-executive Director and a member of the audit committee and nomination committee of the Company and the chairman of the remuneration committee of the Company due to his business engagement/re-arrangement, with effect upon the conclusion of the AGM. Upon the conclusion of the AGM, Mr. HUANG Bin has become a non-executive Director and the audit committee of the Company now comprises of Mr. HUANG Bin and Mr. WANG Rui (as members) and Mr. PU Tianruo (as the chairman). Mr. WANG Rui is currently the vice president of Beijing Unimed Charitable Foundation. Mr. WANG served as a director of Beijing Mianshi Investment Group Co. Ltd. from 2012 to 2017.

3SBio Inc. Presents at Credit Suisse 2019 Asia Healthcare Corporate Day-Hong Kong, Jun-05-2019

3SBio Inc. Presents at Credit Suisse 2019 Asia Healthcare Corporate Day-Hong Kong, Jun-05-2019 . Venue: International Commerce Centre, 1 Austin Road West, Kowloon, Hong Kong.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1530.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1530 Industry Range
Price/Earnings 100.0x
Price/Sales 63.3x
Price/Book 33.6x
Price/Cash Flow 2.1x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3SBIO INC, please visit www.3sbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.